Preclinical News and Research

RSS
Effective method to restore sight to patients with blinding diseases

Effective method to restore sight to patients with blinding diseases

Nano-biosensors along with new  imaging techniques can improve drug targeting in pancreatic cancer

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

New SPECT and MR imaging systems unveiled at SNMMI's 2013 Annual Meeting

New SPECT and MR imaging systems unveiled at SNMMI's 2013 Annual Meeting

Understanding Phelan-McDermid Syndrome

Understanding Phelan-McDermid Syndrome

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

Concert Pharmaceuticals announces initiation of CTP-354 Phase 1 trial in healthy volunteers

Concert Pharmaceuticals announces initiation of CTP-354 Phase 1 trial in healthy volunteers

Paragonix Technologies to present Sherpa Pak Cardiac Transport System during ESOT Congress

Paragonix Technologies to present Sherpa Pak Cardiac Transport System during ESOT Congress

Liver regeneration using cell therapy may be possible, study suggests

Liver regeneration using cell therapy may be possible, study suggests

Doctors create bioengineered blood vessel and implant it in the arm of kidney disease patient

Doctors create bioengineered blood vessel and implant it in the arm of kidney disease patient

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

CytomX collaborates with Pfizer to develop, commercialize more effective antibody-drug conjugates

CytomX collaborates with Pfizer to develop, commercialize more effective antibody-drug conjugates

Scientists develop first dual-action drug against melanoma skin cancer cells

Scientists develop first dual-action drug against melanoma skin cancer cells

MJFF commits up to $10 million to find cure for Parkinson's disease

MJFF commits up to $10 million to find cure for Parkinson's disease

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

Study: Mutations in gene NTRK1 cause a subset of lung cancers

Study: Mutations in gene NTRK1 cause a subset of lung cancers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.